Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms
This re-analysis of survey data (n=985) finds three different clusters (subtypes) of the psychedelic experience. The subtypes, found with machine learning, were associated with reduced anxiety and depression symptoms and other markers of psychological well-being. The subtypes were also highly reproducible across multiple psychedelic substances.
Authors
- Roland Griffiths
- Alan Davis
- Frederick Barrett
Published
Abstract
Background
Subjective experiences seem to play an important role in the enduring effects of psychedelic experiences. Although the importance of the subjective experience on the impact of psychedelics is frequently discussed, a more detailed understanding of the subtypes of psychedelic experiences and their associated impacts on mental health has not been well documented.
Methods
In the current study, machine learning cluster analysis was used to derive three subtypes of psychedelic experience in a large (n = 985) cross sectional sample.
Results
These subtypes are not only associated with reductions in anxiety and depression symptoms and other markers of psychological wellbeing, but the structure of these subtypes and their subsequent impact on mental health are highly reproducible across multiple psychedelic substances.
Limitations
Data were obtained via retrospective self-report, which does not allow for definitive conclusions about the direction of causation between baseline characteristics of respondents, qualities of subjective experience, and outcomes.
Conclusions
The present analysis suggests that psychedelic experiences, in particular those that are associated with enduring improvements in mental health, may be characterized by reproducible and predictable subtypes of the subjective psychedelic effects. These subtypes appear to be significantly different with respect to the baseline demographic characteristics, baseline measures of mental health, and drug type and dose. These findings also suggest that efforts to increase psychedelic associated personal and mystical insight experiences may be key to maximizing beneficial impact of clinical approaches using this treatment in their patients.
Research Summary of 'Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms'
Introduction
Depression and anxiety are common, disabling disorders with limited response to existing treatments, prompting renewed interest in alternative approaches. Earlier clinical trials and naturalistic surveys have reported substantial and sometimes durable reductions in depression and anxiety following psychedelic-assisted experiences, with prior work implicating facets of the subjective experience—particularly mystical-type experiences and psychological insight—in mediating benefit. However, most prior analyses have used a top-down approach testing a small number of hypothesised relationships (for example mystical-type effects versus outcome), leaving unexplored the possibility that there are reproducible subtypes of psychedelic experiences that map differently onto mental health outcomes. Nikolaidis and colleagues set out to identify data-driven subtypes of the acute psychedelic experience and to test whether these subtypes predict changes in depression, anxiety and related measures. Specifically, the study asked two main questions: whether distinct subtypes (spanning mystical, insight and challenging experiences) could be derived and whether those subtypes replicate across LSD and psilocybin subsamples and show consistent relationships to symptom change. To address these aims the authors re-analysed data from a large cross-sectional online survey using hierarchical clustering applied to item-level measures of subjective experience.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Topics
- Authors
- APA Citation
Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2023). Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. Journal of Affective Disorders, 324, 239-249. https://doi.org/10.1016/j.jad.2022.12.042
References (28)
Papers cited by this study that are also in Blossom
Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V. et al. · ACS Pharmacology and Translational Science (2021)
Argento, E., Strathdee, S. A., Tupper, K. et al. · BMJ Open (2017)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Davis, A. K., Barsuglia, J. P., Lancelotta, R. et al. · Journal of Psychopharmacology (2018)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Show all 28 referencesShow fewer
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Goldberg, S. B., Pace, B. T., Nicholas, C. R. et al. · Psychiatry Research (2020)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Lancelotta, R., Davis, A. K. · Journal of Psychoactive Drugs (2020)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Olson, D. E. · ACS Pharmacology and Translational Science (2020)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)
Williams, T. M., Davis, A. K., Xin, Y. et al. · Drugs Education Prevention and Policy (2020)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Cited By (5)
Papers in Blossom that reference this study
Henningfield, J. E., Barrett, F. S., Evans, S. M. et al. · Journal of Psychopharmacology (2026)
Levin, A. W., Lancelotta, R., Sepeda, N. D. et al. · PLOS ONE (2024)
Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)
Heinzerling, K. G., Sergi, K., Linton, M. et al. · Frontiers in Psychiatry (2023)
Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.